Abbott receives U.S. FDA clearance for two new over-the-counter continuous glucose monitoring systems

image credit- shutterstock

Abbott announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo and Libre Rio, which are based on Abbott's FreeStyle Libre continuous glucose monitoring technology. The newly cleared systems have been intentionally designed to meet different needs – Lingo for consumers who want to better understand and improve their health and wellness, and Libre Rio for adults with type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.

Abbott's consumer biowearable, Lingo, is designed to track glucose levels and provide personalized insights and customized coaching to help people create healthy habits, retrain their metabolism and improve their overall well-being. 

The Lingo system combines a biosensor that is worn on the upper arm for 14 days and continuously streams glucose data to a coaching application on a smart phone – translating the body's language and giving insights on the person's reaction to food, exercise and life's daily stressors.